Bevacizumab (Avastin) was safely added to pembrolizumab (Keytruda) in patients with active melanoma brain metastases who had not previously received a PD-1 inhibitor, according to data from a small phase 2 trial published in the Journal of Clinical Oncology.
2025
FDA Grants Breakthrough Therapy to IDE196 in Primary Uveal Melanoma
The FDA granted Breakthrough Therapy designation to IDE196 for the neoadjuvant treatment of primary uveal melanoma when enucleation has been recommended.
Novel radiosurgical platform to treat a case of uveal melanoma
Uveal melanoma, which primarily affects Caucasian patients, is the most common primary intraocular tumor in adults2 that most often affects the choroid (90%), ciliary body (6%), and iris (4%)
Breakthrough provides potential for precise melanoma treatment
A major step forward has been made in predicting how well melanoma patients would respond to treatment, thanks to world-leading University of Otago—?t?kou Whakaihu Waka research.